NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at BTIG Research in a report released on Monday, Benzinga reports. They currently have a $10.00 price target on the stock. BTIG Research’s price objective indicates a potential upside of 187.36% from the stock’s previous close.
A number of other research firms have also weighed in on NRXP. UBS Group reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research note on Wednesday, August 26th. Zacks Research downgraded NRx Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, August 26th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating on shares of NRx Pharmaceuticals in a research report on Tuesday, August 25th. Finally, Wall Street Zen downgraded NRx Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Five equities research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, NRx Pharmaceuticals has an average rating of “Hold” and an average target price of $34.50.
Check Out Our Latest Report on NRXP
NRx Pharmaceuticals Trading Up 2.4%
NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.33). The company had revenue of $1.10 million for the quarter, compared to analysts’ expectations of $1.33 million. As a group, analysts anticipate that NRx Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.
Institutional Trading of NRx Pharmaceuticals
Institutional investors have recently bought and sold shares of the business. Anson Funds Management LP increased its position in shares of NRx Pharmaceuticals by 50.3% in the fourth quarter. Anson Funds Management LP now owns 3,043,957 shares of the company’s stock valued at $8,249,000 after buying an additional 1,018,853 shares in the last quarter. Commonwealth Equity Services LLC purchased a new position in shares of NRx Pharmaceuticals during the 4th quarter valued at approximately $994,000. Bleakley Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the 4th quarter valued at $318,000. AdvisorShares Investments LLC grew its stake in NRx Pharmaceuticals by 28.2% in the 1st quarter. AdvisorShares Investments LLC now owns 420,467 shares of the company’s stock valued at $896,000 after acquiring an additional 92,463 shares during the period. Finally, Vanguard Group Inc. increased its holdings in NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock worth $1,765,000 after acquiring an additional 82,781 shares in the last quarter. 4.27% of the stock is owned by institutional investors and hedge funds.
About NRx Pharmaceuticals
NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.
Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.
Featured Articles
- Five stocks we like better than NRx Pharmaceuticals
- Analysts Are Punting Their Calls Into the Next Quarter After Adobe’s Mixed Earnings
- Institutional Money Is Pouring Into These 2 Altcoin ETFs
- The End of Big Tech Buybacks? Only One Hyperscaler Is Still Repurchasing Shares
- 3 Dividend Kings to Buy While They’re Still Beaten Down
Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
